i mean, it's embarrassing almost celgene is up 49% year to date, gilead's up 4% >> bristol's buying celgene, that's why >> tell me this two years ago. >> but it's still gilead more expensive than celgene even with a do nothing track record. >> i still -- i just don't know why you go to a sell stock when you -- look, even if you don't believe the valuation matters, ten times earnings, 4% dividend yield. >> when do you go to a sell, jim? >> not there would you -- i mean, you're putting me on the spot but i'm answering your question. >> not trying to put you on the spot i'm just saying -- >> the correct answer is 200 points ago >> analysts are criticized all the time for just going there. if you don't believe in it, why not go there >> i can't tell if you're on me or the analyst but let me point this out >> i don't mean you, i mean the analyst. >> here's the thing. you know what i love is when an analyst makes an against the grain call i said, don't buy these stocks at 35 times, okay? i would have loved to see an analyst on nvidia say that at 250, not at 145. that's the sort of call that i'm t

fell on hard times celgene for $74 billion in a game changing acquisition. deal was very comfort. the stock got slammed on the news a few weeks later starboard value comes in and tries to block the deal man, these guys are busy bristol-myers is a little different because this is a case where i think the activists straight-up got it wrong we at giovanni cafarrio, had hi on several times his company's key oncology drug has been crushed by the competition from merck, this keytruda drug that's so good but with celgene, i think they'll become the largest player in the oncology space eventually management won. the deal was approved by shareholders of both companies and all that's left is for the transaction to close and the stock is finally starting to get some traction. ben bristol-myers reported, the stock has rallied for six straight session up up more than 5% ten times everything, too cheap. it guess higher. last but not last, there are activists who will try to take on truly herculean tasks, like cleaning out the augean stables, the stables that is bed, bath

this time celgene is merging with bristol i like that. i know people are very skeptical. i think bristol's the one to buy. let's go to dave in illinois hey, dave, how you been? >> caller: dr. cramer. well, apart from protracted tariff uncertainty, global economic slowdown and impending u.s. two-year ten year yield conversion, i'm doing just fine. how about you? >> you probably left out the pbh forecast, dave stick around and watch the show. you'll get that, too add to the woes. what's going on? >> caller: you've got it, my friend jim, my stock today is in the medical device space i like intuitive surgical, isrg. >> i know, man i'm a da vinci fan i've seen it in action i think it's doing well. this stock has come under severe selling pressure dave, i bet if you buy it and put it away for years, you're going to have a good one i am shocked at the decline. every time i look at it i don't see a good reason for it i think it's the zeitgeist of the moment let's go to gordon in florida. gordon >> caller: how you doing >> i don't know, gordon. today was a hard day a lot of good s

for us, china is a huge opportunity for us we're really encouraged by the momentum in areas like celgene and we're actively investing to help solve some of the problems to get those technologies into patients' lives around the world >> are there raw material costs that you're most keyed to? >> no, our model isn't particularly sensitive to the raw material cost inputs, you know, generally. >> michael stubblefield, thanks for joining us here today. >> thank you >> on the day that avantor goes public stock's up almost 3% right now >> a great day for avantor >> a great day for ipos in general. >> as "game of thrones" comes to an end, we have a look at it have massive market for betting on how it's all going to wrap up the dow is hanging on to 25 points every day, visionaries are creating the future. so, every day, we put our latest technology and unrivaled network to work. the united states postal service makes more e-commerce deliveries to homes than anyone else in the country. >>> welcome back "game of thrones" coming to an end this sunday with fans eagerly awaiting to see who will asce as

has pulled back about 15% just fry highs in march alone and of course, the ongoing acquisition of celgene will wrap up in the third quarter and bristol beat handily over the next week and wo we've started to move in the highest level and it's gotten quite oversold and it's dropped to 70 down to levels in the low 40s. we've bottomed out in exactly the same levels in last october and in january and we've turned up to new weekly highs and those are also important and i think bristol-myers can rally to the high 40s and that's the other way to replay this and the other way is pfizer. take a look at pfizer and it peaked back in 1999 and 2000 it's want been above that level since then so what has it done this year? since last november and december we pulled back from levels right here in the high 30s about 10% so if anything, it's a very good risk/reward at a time when the sector should be starting to turn higher and they buy pfizer and this stock can move back into the low 40s and those are two picks and i like bristol-myers and i like pfizer. health care technically trying to show signs of nea

going public 90 days ago, a former management team that got bought owl to celgene and went public 90ays ago and they're just starting to get initiation coverage on their company. would now be a good time to start? >> that stock just got hammered. again, i happen like to like the biopharmas i don't like them out of the chute. if something was going to buy it -- a lot are due for takeovers they would have bought already. for spec if you put it away you'll be okay guy, this beyond meat could be interesting but i don't want it to come in too hot you have my blessing to do speck live buying. i'm hitting the books to find out how earnings check up with cheg how should you be playing the tech titan i'm eyeing it after earnings and rapid-fire, tonight's edition of "the lightning round" so stay with cramer. through the at&t network, edge-to-edge intelligence gives you the power to see every corner of your growing business. from finding out what's selling best... to managing your fleet... to collaborating remotely with your teams. giving you a nice big edge over your competition. that's the po

who can remember that far back but celgene was a small company.company it was genentech before. >> that's a good point. >> so you can compete if you have a good value proposition for the patient. and in ms, i think we have a great value proposition. we're coming in with a drug and a class of drugs which is known to work. our drug has worked in phase two. the drug that's on the market did $2 billion in its first full year of sales. it's on its way for $4 billion in the second year of sales. so it's a huge market. they're expecting just the cd-20, which is our target part of that market to be $10 billion. so we're going to come in. we're going to come in with a convenient once every six-month dosing it's going to be a one-hour infusion so super convenient to the patient. it's also great for the infusion suites they can move patients in and out very easily. and also, look, we're a tiny company. we don't care that much about price. so we can be very strategic, very competitive on pricing. and again, price is not just about lowering the price it's abou

there are exciting new technologies being developed around the world, celgene therapy is an opportunitynfrastructure to bring innovative solutions to that space, to help make good on the promise that our customers are .etting out of the lab scarlet: thank you for joining us. this is bloomberg. ♪ bloomberg. ♪ >> time now for options inside. happy friday. what a week it has been. we had that big selloff monday. the last week was the worst week of the year. we are looking at declines kleins for the major averages. the first time we are seeing a four-week decline for the dow. what do you make of this, especially the yen of since april and the havens and smart money going in that direction and we could have more weakness. >> even before we had some headlines late this afternoon, giving us another reason to sell stocks, havens were performing as stocks rebounded. 2.4%, year is below strength in jpy consistently. that there isll macro risks being priced into cash. you don't see that same risk in the options market. >> that is interesting. andere chatting before hand have a great chart we have

celgene is not alone. ie -- pay for delay deals will keep the competitor of the market in the u.s. until 20 23. ashley craig is a small business owner from texas. she needs hume era to treat -- treat her chronic illness. she has spent years grappling why do drug companies charge so much? because they can. drug companies should profit when they develop innovative new drugs but we are way out of balance and it is costing us in -- finances how health outcomes and lives. and the days law of monopoly pricing power without text. negotiations, force transparency from drug middlemen. are abusing our system to extend their government granted monopolies and block competition. a whole array of tactics. anticompetitive pay for delay deals, patent thickets, ever , petitions before the fda. i would be pleased to talk more about the bills many of you have introduced during the q&a. he direct medicare price negotiation. our current system is not working. we pay two to three times what other countries pay for the same drugs. one big reason is other countries negotiate. we should too. we need more t